Memphasys Secures South-East Asian Commercialization Agreement
Key points
- Memphasys enters exclusive agreement with TMSC Vietnam for Felix† system
- First commercial partnership in South-East Asia, expanding international network
- Two-year contract valued at A$530,000, with growth expected post-regulatory approval
Full summary
Memphasys Limited, an Australian-based reproductive biotechnology company, has announced the signing of an exclusive commercialization agreement with TMSC Viet Nam Medical Technology Company Limited for the Felix† sperm separation system in Vietnam. This agreement represents Memphasys' first commercial partnership in South-East Asia, expanding its international distribution network. The two-year contract is valued at A$530,000, with the potential for growth as quarterly cartridge orders increase following regulatory approval, expected in August 2026. Vietnam's IVF sector is growing rapidly, driven by rising infertility rates and increasing healthcare investment, making it an ideal market for advanced sperm selection technologies like Felix†. TMSC Vietnam, a leading Hanoi-based medical technology company, will work alongside Memphasys to drive product education and clinical adoption, leveraging local regulatory expertise and established relationships across the Vietnamese healthcare system.
Guidance
Two-year contract valued at A$530,000, with growth expected post-regulatory approval.
Outlook
Memphasys continues to build its international commercial footprint in high-value fertility markets, with key milestones including regulatory approval in Vietnam and the commencement of in-market testing activities.
Summary generated by a large language model. Please interpret with care.